Earnings Scorecard & Analyst Reports Biofrontera (NASDAQ:BFRA)

0
703

Earnings results for Biofrontera (NASDAQ:BFRA)

Biofrontera AG is expected* to report earnings on 11/11/2020 after market close. The report will be for the fiscal Quarter ending Sep 2020. The reported EPS for the same quarter last year was $-0.59.

Biofrontera last posted its earnings results on August 26th, 2020. The reported $0.04 earnings per share for the quarter. The company had revenue of $10.62 million for the quarter. Biofrontera has generated $0.00 earnings per share over the last year. Biofrontera has confirmed that its next quarterly earnings report will be published on Wednesday, November 11th, 2020.

Analyst Opinion on Biofrontera (NASDAQ:BFRA)

2 Wall Street analysts have issued ratings and price targets for Biofrontera in the last 12 months. Their average twelve-month price target is $9.50, predicting that the stock has a possible upside of 37.09%. The high price target for BFRA is $11.00 and the low price target for BFRA is $8.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of “Buy.”

Biofrontera has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $9.50, Biofrontera has a forecasted upside of 37.1% from its current price of $6.93. Biofrontera has received no research coverage in the past 90 days.

Dividend Strength: Biofrontera (NASDAQ:BFRA)

Biofrontera does not currently pay a dividend. Biofrontera does not have a long track record of dividend growth.

Insiders buying/selling: Biofrontera (NASDAQ:BFRA)

In the past three months, Biofrontera insiders have not sold or bought any company stock.

Earnings and Valuation of Biofrontera (NASDAQ:BFRA

The P/E ratio of Biofrontera is -6.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Biofrontera is -6.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Biofrontera has a P/B Ratio of 13.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

More latest stories: here